Daunorubicin

Generic Name: Daunorubicin

Brand Names: Cerubidine, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₀

CAS Number: 20830-81-3

Unique Ingredient Identifier: ZS7284E0ZP

Background: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.

Indication: For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
...

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor

Associated Therapies: -

Clinical Trials

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: ID cytarabine
Drug: Idarubicin
Drug: Cyclosporine
Drug: HD Cytarabine
Drug: Methotrexate
Drug: vosaroxin
Drug: Daunorubicin
Drug: Mycophenolic acid (MPA)
Drug: Dexamethasone
Drug: Venetoclax

First Posted Date: 2015-04-15

Last Posted Date: 2024-08-07

Lead Sponsor: University Hospital, Angers

Target Recruit Count: 3100

Registration Number: NCT02416388

Locations: 🇫🇷
CH Amiens Hôpital Sud, Amiens, France
🇫🇷
CHU Angers, Angers, France
🇫🇷
CH Victor Dupouy, Argenteuil, France

and more 53 locations

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
AML
Leukemia

Interventions: Drug: Selinexor
Drug: Daunorubicin
Drug: Cytarabine

First Posted Date: 2015-03-31

Last Posted Date: 2022-10-03

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 21

Registration Number: NCT02403310

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 3

Completed

Conditions: Leukemia, Acute Lymphoblastic

Interventions: Drug: Dexamethasone
Drug: Blinatumomab
Drug: Vincrisitne
Drug: Daunorubicin
Drug: Methotrexate
Drug: Ifosfamide
Drug: PEG-asparaginase
Drug: Erwinia-asparaginase

First Posted Date: 2015-03-20

Last Posted Date: 2024-05-29

Lead Sponsor: Amgen

Target Recruit Count: 111

Registration Number: NCT02393859

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Entospletinib
Drug: Daunorubicin
Drug: Decitabine
Drug: Cytarabine
Drug: Azacitidine

First Posted Date: 2015-01-22

Last Posted Date: 2019-11-15

Lead Sponsor: Gilead Sciences

Target Recruit Count: 148

Registration Number: NCT02343939

Locations: 🇺🇸
University of Kansas Medical Center Research Institute, Inc, Fairway, Kansas, United States
🇩🇪
Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, Germany
🇺🇸
Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States

and more 14 locations

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Acute Myelogenous Leukemia

Interventions: Drug: Standard dose cytarabine for induction
Drug: SGN-CD33A
Drug: High dose cytarabine for consolidation
Drug: Daunorubicin

First Posted Date: 2014-12-29

Last Posted Date: 2018-05-09

Lead Sponsor: Seagen Inc.

Target Recruit Count: 116

Registration Number: NCT02326584

Locations: 🇺🇸
James Cancer Hospital / Ohio State University, Columbus, Ohio, United States
🇺🇸
Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas, Texas, United States

and more 10 locations

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia (ALL)

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Drug: Mitoxantrone
Drug: PEG-asparaginase
Drug: Vincristine
Drug: Intrathecal (IT) Methotrexate
Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
Drug: 6-Mercaptopurine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin

First Posted Date: 2014-12-01

Last Posted Date: 2024-07-16

Lead Sponsor: Amgen

Target Recruit Count: 130

Registration Number: NCT02303821

Locations: 🇺🇸
Childrens Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States
🇺🇸
West Virginia University Medicine Childrens, Morgantown, West Virginia, United States
🇹🇷
Medical Park Bahcelievler Hastanesi, Istanbul, Turkey

and more 116 locations

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

Phase 2

Completed

Conditions: Newly Diagnosed AML With FLT3 Activating Mutations

Interventions: Drug: crenolanib
Drug: cytarabine
Drug: daunorubicin
Drug: idarubicin

First Posted Date: 2014-11-05

Last Posted Date: 2024-02-02

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 44

Registration Number: NCT02283177

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 6 locations

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Gilteritinib
Drug: Idarubicin
Drug: Cytarabine
Drug: Daunorubicin

First Posted Date: 2014-09-10

Last Posted Date: 2024-11-05

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 80

Registration Number: NCT02236013

Locations: 🇺🇸
Site US10003, Los Angeles, California, United States
🇺🇸
Site US10013, New Haven, Connecticut, United States
🇺🇸
Site US10004, Chicago, Illinois, United States

and more 7 locations

Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Phase 2

Terminated

Conditions: High-risk Myelodysplastic Syndrome (MDS)
Acute Myeloid Leukemia (AML)

Interventions: Drug: Cytarabine
Drug: Volasertib
Drug: Daunorubicin
Drug: Mitoxantrone

First Posted Date: 2014-07-23

Last Posted Date: 2018-02-28

Lead Sponsor: University of Ulm

Target Recruit Count: 6

Registration Number: NCT02198482

Locations: 🇩🇪
Hospital Aschaffenburg, Aschaffenburg, Germany
🇩🇪
Helios Hospital Bad Saarow, Bad Saarow, Germany
🇩🇪
Vivantes Hospital Neukölln, Berlin, Germany

and more 42 locations

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

First Posted Date: 2014-04-14

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 847

Registration Number: NCT02112916

Locations: 🇺🇸
Covenant Children's Hospital, Lubbock, Texas, United States
🇺🇸
UMC Cancer Center / UMC Health System, Lubbock, Texas, United States
🇦🇺
Monash Medical Center-Clayton Campus, Clayton, Victoria, Australia

and more 209 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy